01—Abstract
Summary
Summary of the 8-K filed April 14, 2026. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines (ONC) furnished this 8-K under Item 2.02 to disclose supplemental financial information from its 2025 Annual Report, filed April 14, 2026 with the Shanghai Stock Exchange STAR Market under PRC rules.
The filing itself is not a traditional earnings release. It contains no new guidance, no commentary on drivers, and no full financial statements. Its substance is in Exhibit 99.1, which presents U.S. GAAP-basis regional gross margin, R&D allocated by program, and production/sales/inventory data, plus a qualitative summary of differences between U.S. GAAP and PRC GAAP.
The disclosed numbers show strong 2025 top-line growth. Total revenue was about $5.34 billiona, up roughly 40% from $3.81 billion in 2024. Ex-China revenue grew about 53% to $3.66 billion, while China grew about 19% to $1.68 billion.
Blended gross margin rose from roughly 84%b to roughly 87%, driven mainly by China gross margin improving from 62.9% to 66.6%. Ex-China margin was essentially flat at about 97%. Ex-China cost of goods rose about 55%, a faster rate than the revenue-based margin gain would suggest, so mix and scale effects are worth monitoring.
R&D spending rose about 10% to $2.15 billionc. Mix shifted toward newer assets: sonrotoclax R&D increased about 77% to $177 million, and BGB-16673 rose more than fourfold to $94 million, while BRUKINSA and TEVIMBRA R&D declined. External R&D grew about 18%, while internal R&D grew about 5%.
R&D collaboration project spending fell about 45%d. Investors should note that the filing does not explain the drivers of these changes, and that the Chinese-language STAR report, not this exhibit, is the primary source for the PRC-basis figures.
02—Key points
Key Highlights
- Total 2025 revenue of about $5.34B, up about 40% year over year from $3.81B in 2024.
- Ex-China revenue rose about 53% to $3.66B, accounting for roughly 69% of total revenue; China revenue grew about 19% to $1.68B.
- Blended gross margin improved to about 87.5% from about 84.4%, led by China margin expansion from 62.9% to 66.6%; ex-China margin was steady near 97%.
- Total R&D expense of $2.15B, up about 10%; external R&D rose about 18% to $859M while internal R&D rose about 5% to $1.29B.
- Sonrotoclax R&D increased about 77% to $177M and BGB-16673 R&D rose to $94M from $20M, signaling pipeline prioritization toward these assets.
- BRUKINSA and TEVIMBRA R&D spending declined about 24% and 18%, respectively, and R&D collaboration project spending fell about 45%.
- 2025 included a 2025 transfer of royalty rights to a third party for a fixed upfront cash payment, which is accounted for as a liability under U.S. GAAP and as deferred revenue under PRC GAAP.
03—Questions
Frequently Asked Questions
Why did BeOne file this 8-K, and is it an earnings release?
The 8-K was filed to furnish supplemental information required by PRC securities rules alongside the 2025 STAR Market Annual Report. It is not a full earnings release. It does not include new guidance or full U.S. GAAP financial statements, and the exhibit is furnished rather than filed for Exchange Act liability purposes.
How strong was revenue growth in 2025, and where did it come from?
Total revenue rose about 40% to roughly $5.34B. Ex-China revenue grew about 53%, outpacing China's roughly 19% growth, so international sales were the main contributor. The filing does not break out revenue by product or explain the specific drivers.
Did profitability improve?
Gross margin improved on a blended basis, from about 84% to about 87.5%, mainly due to China margin gains. Ex-China gross margin was flat at about 97%. The filing does not provide operating income, net income, or cash flow, so overall profitability cannot be assessed from this document alone.
How is R&D spending changing, and what does it signal?
Total R&D rose about 10% to $2.15B, with a clear shift toward sonrotoclax and BGB-16673, whose R&D roughly increased 77% and more than quadrupled, respectively. Spending on BRUKINSA, TEVIMBRA, and R&D collaboration projects declined. This suggests a pipeline prioritization toward newer assets, though the company has not provided commentary on it in this filing.
Why do U.S. GAAP and PRC GAAP figures differ, and which should investors use?
The exhibit notes differences in share-based compensation expense timing, lease accounting, and royalty sale accounting. For example, the royalty transfer is recorded as a liability under U.S. GAAP but as deferred revenue under PRC GAAP. U.S. GAAP figures are generally more comparable with the company's SEC filings, so investors should use them for U.S. analysis and treat PRC-basis figures as supplemental.
04—Continue